The Transition to Disease-Modifying Treatments

For years, Alzheimer's disease (AD) treatment focused on relieving symptoms with medications such as donepezil, galantamine, rivastigmine, and memantine. Introduced in the late 1990s and early 2000s, these drugs help improve memory, attention, and daily functioning but do not change the disease's progression. Recognizing this limitation, researchers have developed disease-modifying treatments like lecanemab (Leqembi) that address the root cause of AD.

Lecanemab, which received FDA approval in January 2023 and insurance coverage by mid-2023, is the first treatment to slow disease progression by targeting early amyloid plaque buildup in the brain. Unlike traditional therapies that only manage symptoms, lecanemab is the first true disease-modifying therapy for Alzheimer's, offering the potential to delay cognitive decline when started early.

How Lecanemab Works

Lecanemab is a monoclonal antibody specifically designed to recognize and bind to amyloid plaques that form early in Alzheimer's. Administered as an intravenous infusion twice monthly for 18 months, it aims to enhance the brain's ability to clear amyloid plaques effectively. These plaques are misfolded proteins that accumulate between neurons, disrupting normal brain function. By directly targeting the plaques, lecanemab seeks to reduce their buildup before causing irreversible neuronal damage. The treatment also decreases neurodegenerative biomarkers, such as phosphorylated tau and neuroinflammatory markers. Early intervention is crucial, as plaques take years to accumulate to levels that cause cognitive and functional decline.

Clinical Evidence and Predictive Factors

The Clarity AD trial provided significant insights into lecanemab's efficacy over 18 months, comparing it with a placebo. The study assessed whether reducing amyloid plaques would slow cognitive and functional decline. Results were promising: lecanemab significantly reduced amyloid levels, associated with a 30% slowing in functional decline across participants. However, individual responses varied.

• Amyloid Reduction: Significant reduction in brain amyloid levels.
• Functional Outcomes: Approximately 30% slower decline in cognitive and functional measures.
• Predictive Factors: Patients with mild cognitive impairment (MCI) experienced better outcomes than those with moderate dementia, highlighting the importance of early intervention.
• Biomarker Correlation: Lower tau levels, a marker of neuronal damage, predict better responses to treatment.

These findings emphasize lecanemab's potential as a disease-modifying therapy, particularly when started early in AD. Early intervention appears to produce the best outcomes, as participants with MCI showed slower disease progression and better maintained functional abilities. This aligns with tau protein levels, a biomarker of Alzheimer's burden. Elevated tau proteins indicate neuronal damage, and your current levels, slightly above normal but still low, suggest a promising response to lecanemab, supporting early therapy initiation.

Side Effects and Considerations

Since its introduction, lecanemab has been generally well-tolerated. Common side effects include mild infusion-related reactions, such as slight allergic responses, which are typically managed with steroids and antihistamines during treatment. Some patients report more side effects from the antihistamines than the infusion itself. Mild headaches are also common and respond well to over-the-counter medications like Tylenol or gabapentin.

A significant consideration is a side effect known as ARIA (amyloid-related imaging abnormalities), occurring when amyloid plaques are rapidly cleared. ARIA has two types: ARIA-E, involving mild brain edema (swelling), and ARIA-H, involving small brain microbleeds. In the Clarity AD trial, ARIA-E occurred in about 12.5% of participants, often without symptoms or presenting mild symptoms like headaches or dizziness, resolving within one to two months.

ARIA-H, or microbleeding, was observed in about 17.5% of participants, with approximately 10% of those in the placebo group also experiencing microbleeds. This is likely due to cerebral amyloid angiopathy (CAA), common in Alzheimer's, where amyloid plaques form around blood vessels, making them brittle. To reduce risk, lecanemab is not prescribed to patients with pre-existing microbleeds, identified through MRI scans.

Personal Risk Assessment

Careful patient selection and monitoring optimize safety and efficacy.

• MRI Screening: Excludes patients with pre-existing microbleeds or major vascular damage, reducing ARIA risk.
• Genetic Testing: Identifies APOE genotype to assess ARIA likelihood.
• Individualized Management: Adjustments, such as pausing anticoagulants, further reduce bleeding risks.

Patients with mild symptoms, low tau levels, and favorable genetic profiles are ideal candidates for lecanemab.

Challenges and Future Directions

Despite its promise, lecanemab faces challenges:

• Access: High costs, specialized infusion facilities, and MRI monitoring may limit availability.
• Safety Profile: Long-term effects of ARIA and overall treatment safety require further study.
• Efficacy Debate: While benefits are evident, some experts question the clinical significance of observed improvements.

These considerations highlight the need for continued research, infrastructure development, and cost management to maximize lecanemab's impact.

Conclusion and Treatment Plan

Lecanemab represents a transformative step in Alzheimer's care, transitioning from symptomatic management to modifying the disease's trajectory. By addressing the underlying biology of AD, it offers patients the potential for prolonged cognitive stability and improved quality of life.

For individuals in early disease stages, lecanemab provides hope and an opportunity to slow progression, reinforcing the importance of early detection and personalized treatment strategies. Early amyloid targeting is critical, as plaques accumulate years before symptomatic AD. Patients beginning treatment during MCI or early-stage AD experience the most benefit, maintaining cognitive and functional abilities longer than those starting later. This underscores the importance of early diagnosis and intervention for optimal outcomes.